The identification and development of novel nontoxic
phytochemicals that target
androgen and
androgen receptor (AR) signaling remains a priority for
prostate cancer (PCA) control. In the present study, we assessed the antiandrogenic efficacy of
isosilybin B employing human PCA LNCaP (mutated AR), 22Rv1 (mutated AR) and LAPC4 (wild-type AR) cells.
Isosilybin B (10-90 microM) treatment decreased the AR and
prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells.
Isosilybin B treatment also inhibited
synthetic androgen R1881-induced nuclear localization of AR, PSA expression and cell growth, and caused G(1) arrest. In mechanistic studies identifying AR degradation,
isosilybin B caused increased phosphorylation of Akt (Ser-473 and Thr-308) and Mdm2 (Ser-166), which was linked with AR degradation as pretreatment with PI3K inhibitor (LY294002)-restored AR level. Further, overexpression of
kinase-dead Akt largely reversed
isosilybin B mediated-AR degradation suggesting a critical role of Akt in AR degradation. Antibody pull-down results also indicated that
isosilybin B treatment enhances the formation of complex between Akt, Mdm2 and AR, which promotes phosphorylation-dependent AR ubiquitination and its degradation by
proteasome. Together, present findings identify a novel mechanism for
isosilybin B-mediated anticancer effects in human PCA cells.